Yuasa Shinsuke
Department of Cardiology, Keio University School of Medicine.
Circ J. 2022 May 25;86(6):919-922. doi: 10.1253/circj.CJ-21-0978. Epub 2022 Feb 19.
Cardiovascular disease (CVD) is a major global health concern. Several therapeutic strategies for CVDs are available, such as medicine, cardiac assist devices, and heart transplantation. However, they are insufficient for the treatment of severe CVD. To develop novel, innovative treatment approaches for CVDs, it is imperative to understand the underlying pathophysiology and to undertake basic research on this facet. The generation of induced pluripotent stem (iPS) cells has opened avenues for developing new strategies for disease analysis and drug development. This technology has made it possible to obtain pluripotent stem cells from patients with genetic disorders, model the disease in a dish, and use such cells for future regeneration therapy. Meanwhile, artificial intelligence (AI), which is widely used for big data analysis in basic research, has potential in various applications in medicine. New tools such as iPS cells and AI can provide much needed novel insights into CVDs. This review focuses on the recent progress in cardiovascular research using these new technologies.
心血管疾病(CVD)是全球主要的健康问题。目前有多种针对心血管疾病的治疗策略,如药物治疗、心脏辅助装置和心脏移植。然而,这些方法对于严重心血管疾病的治疗并不充分。为了开发新颖、创新的心血管疾病治疗方法,必须了解其潜在的病理生理学,并在此方面进行基础研究。诱导多能干细胞(iPS细胞)的产生为疾病分析和药物开发新策略的发展开辟了道路。这项技术使从患有遗传疾病的患者身上获取多能干细胞、在培养皿中模拟疾病以及将这些细胞用于未来的再生治疗成为可能。同时,在基础研究中广泛用于大数据分析的人工智能(AI)在医学的各种应用中具有潜力。诸如iPS细胞和AI等新工具可以为心血管疾病提供急需的新颖见解。本综述重点关注使用这些新技术在心血管研究方面的最新进展。